Literature DB >> 240661

The disposition of ftorafur in rats after intravenous administration.

A M Cohen.   

Abstract

The excretion, distribution, and metabolism of ftorafur was studied in rats following a single intravenous injection of radioactively labeled drug. Approximately 55% of the administered radioactivity was excreted as 14CO2, while 23% was eliminated via the urinary route in 24 hr. Less than 2% was excreted in the feces. The major excretory product found in the urine was unmetabolized ftorafur. However, the proportions of radioactively labeled metabolites such as 5-fluorouracil and urea increased with time after injection. The half-life of ftorafur in plasma was estimated to be approximately 5 hr. The drug was fairly evenly distributed to liver, small intestine, spleen, kidney, and brain. Highest initial concentrations were found in the liver, which also retained more drug for a longer period than the other tissues. The liver was also found to contain the highest initial proportions of 5-fluorouracil and its metabolites. The results obtained are consistent with the suggestion that ftorafur may be a depot form of 5-fluorouracil and that the liver may be the primary site at which the latter drug is released in vivo.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 240661

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Cytotoxicity of three novel fluoropyrimidines in cultured L1210 murine lymphocytic leukemia cells.

Authors:  A M Shipp; M H Holshouser; P W Ferguson
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

Review 2.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

3.  Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.

Authors:  S Kawata; S Noda; Y Imai; S Tamura; R Saitoh; S Miyoshi; Y Minami; S Tarui
Journal:  Gastroenterol Jpn       Date:  1987-02

4.  Pharmacokinetics of 5-fluorouracil: inter-relationship with biochemical kinetics in monitoring therapy.

Authors:  W Sadee; C G Wong
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

5.  Changes in toxic and antitumor properties of ftorafur by induction or inhibition of the microsomal enzymes activity.

Authors:  G A Belitsky; V M Bukhman; I A Konopleva
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Comparing cell kinetic studies of the effect of ftorafur and 5-fluorouracil on the L 1210 ascites tumor.

Authors:  B Schultze; W Jellinghaus; G Weis; V Müller; W Maurer
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

7.  Pharmacokinetics of ftorafur after intravenous and oral administration.

Authors:  M I Anttila; E A Sotaniemi; M I Kairaluoma; R E Mokka; H T Sundquist
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.